| Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice RK Verma, WA Germishuizen, MP Motheo, AK Agrawal, AK Singh, ... Antimicrobial agents and chemotherapy 57 (2), 1050-1052, 2013 | 78 | 2013 |
| Inhalable Microparticles Containing Nitric Oxide Donors: Saying NO to Intracellular Mycobacterium tuberculosis RK Verma, AK Singh, M Mohan, AK Agrawal, PRP Verma, A Gupta, ... Molecular pharmaceutics 9 (11), 3183-3189, 2012 | 44 | 2012 |
| Inhalable microparticles of nitric oxide donors induce phagosome maturation and kill Mycobacterium tuberculosis RK Verma, AK Agrawal, AK Singh, M Mohan, A Gupta, P Gupta, UD Gupta, ... Tuberculosis 93 (4), 412-417, 2013 | 36 | 2013 |
| Microparticles induce variable levels of activation in macrophages infected with Mycobacterium tuberculosis AB Yadav, P Muttil, AK Singh, RK Verma, M Mohan, AK Agrawal, ... Tuberculosis 90 (3), 188-196, 2010 | 35 | 2010 |
| A novel bispecific antibody targeting EGFR and VEGFR2 is effective against triple negative breast cancer via multiple mechanisms of action N Mohan, X Luo, Y Shen, Z Olson, A Agrawal, Y Endo, DS Rotstein, ... Cancers 13 (5), 1027, 2021 | 33 | 2021 |
| Inhaled therapies for tuberculosis and the relevance of activation of lung macrophages by particulate drug-delivery systems RK Verma, AK Singh, M Mohan, AK Agrawal, A Misra Therapeutic Delivery 2 (6), 753-768, 2011 | 26 | 2011 |
| The devil’s advocacy: When and why inhaled therapies for tuberculosis may not work AB Yadav, AK Singh, RK Verma, M Mohan, AK Agrawal, A Misra Tuberculosis 91 (1), 65-66, 2011 | 22 | 2011 |
| Particulate pulmonary delivery systems containing anti-tuberculosis agents A Gupta, SM Pandya, I Mohammad, AK Agrawal, M Mohan, A Misra Critical Reviews™ in Therapeutic Drug Carrier Systems 30 (4), 2013 | 19 | 2013 |
| Inhalable particles containing isoniazid and rifabutin as adjunct therapy for safe, efficacious and relapse-free cure of experimental animal tuberculosis in one month AK Singh, RK Verma, JK Mukker, AB Yadav, P Muttil, R Sharma, M Mohan, ... Tuberculosis 128, 102081, 2021 | 17 | 2021 |
| pH-sensitive targeting of tumors with chemotherapy-laden nanoparticles: progress and challenges Z Imtiyaz, J He, Q Leng, AK Agrawal, AJ Mixson Pharmaceutics 14 (11), 2427, 2022 | 11 | 2022 |
| Some proteins of M. tuberculosis that localise to the nucleus of THP-1-derived macrophages AK Agrawal, R Ranjan, S Chandra, TK Rout, A Misra, TJ Reddy Tuberculosis 101, 75-78, 2016 | 10 | 2016 |
| Exploring the outer limits of polyplexes A Agrawal, Q Leng, Z Imtiyaz, AJ Mixson Biochemical and biophysical research communications 678, 33-38, 2023 | 4 | 2023 |
| Comparative characterization of different molecular formats of bispecific antibodies targeting EGFR and PD-L1 N Mohan, A Agrawal, Y Shen, KL Winarski, Y Endo, M Dokmanovic, ... Pharmaceutics 14 (7), 1381, 2022 | 4 | 2022 |
| Marked increase in tumor transfection with a truncated branched polymer S Xu, J He, Z Imtiyaz, AK Agrawal, MC Woodle, AJ Mixson The journal of gene medicine 24 (1), e3396, 2022 | 4 | 2022 |
| Lack of factor VIII detection in humans and dogs with an intron 22 inversion challenges hypothesis regarding inhibitor risk P Vir, D Gunasekera, B Dorjbal, D McDaniel, A Agrawal, EP Merricks, ... Journal of Thrombosis and Haemostasis 22 (12), 3415-3430, 2024 | 1 | 2024 |
| Physiochemical and biological characterization of anti-EGFR based bispecific antibodies in triple negative breast cancer (TNBC) models N Mohan, X Luo, Y Shen, Z Olson, A Agrawal, Y Endo, D Rotstein, ... Cancer Research 82 (12_Supplement), 5310-5310, 2022 | 1 | 2022 |
| Inhaled drug combinations S Pandya, A Gupta, R Ranjan, M Sachan, AK Agrawal, A Misra Drug Delivery Systems for Tuberculosis Prevention and Treatment, 213-238, 2016 | 1 | 2016 |
| Goliath loses again AK Singh, A Gupta, M Mohan, AK Agrawal, RK Verma, R Sharma, A Misra | | |
